Top Page
Global Health Limited
(Sydney:GLH)
Global Health Limited (GLH) vs. S&P 500 (SPY)
Global Health Limited Business Overview & Revenue Model
Global Health Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.42M | 8.12M | 7.82M | 6.54M | 7.03M | 5.97M | Gross Profit |
| 886.88K | 2.00M | -2.18M | -663.66K | 812.71K | 626.90K | EBIT |
| -1.19M | -1.22M | -3.73M | -1.98M | -11.52K | -418.08K | EBITDA |
| -1.17M | -1.22M | -7.19M | -1.69M | 57.05K | 489.49K | Net Income Common Stockholders |
| -867.71K | -1.31M | -8.05M | -2.05M | -488.03K | -200.09K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.40M | 2.07M | 2.24M | 6.38M | 4.84M | 666.28K | Total Assets |
| 1.95M | 3.08M | 3.12M | 11.03M | 9.04M | 6.62M | Total Debt |
| 190.14K | 1.03M | 44.94K | 141.83K | 304.11K | 816.41K | Net Debt |
| -1.21M | -1.04M | -2.20M | -6.23M | -4.54M | 150.14K | Total Liabilities |
| 4.70M | 5.98M | 4.74M | 4.95M | 5.00M | 5.47M | Stockholders Equity |
| -2.75M | -2.90M | -1.62M | 6.09M | 4.04M | 1.15M |
| Cash Flow | Free Cash Flow | ||||
| -401.93K | -1.15M | -4.36M | -2.08M | 675.18K | -839.90K | Operating Cash Flow |
| -384.44K | -1.13M | -3.46M | -1.18M | 1.37M | -141.04K | Investing Cash Flow |
| -12.48K | -17.48K | -902.77K | -778.93K | -428.74K | -252.78K | Financing Cash Flow |
| 813.53K | 982.56K | 240.86K | 3.50M | 3.23M | 256.10K |
Global Health Limited Technical Analysis
Global Health Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$17.01M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
57 Neutral | €15.42M | ― | -52.70% | ― | 82.90% | -89.41% | |
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
50 Neutral | AU$723.24M | ― | -112.97% | ― | ― | -84.82% | |
36 Underperform | $3.98M | ― | -119.28% | ― | ― | 64.10% | |
32 Underperform | AU$4.63M | ― | ― | -11.00% | 86.56% |
Global Health Limited Corporate Events
Global Health Limited has secured a three-year contract with Very Special Kids to implement its MasterCare Plus Client Management System, tailored for paediatric palliative care. This deployment will enhance digital healthcare operations, streamline service delivery, and improve clinician-family engagement through its SaaS solutions, including secure messaging and digital front door platforms. The agreement, with options for extension, is expected to strengthen Global Health’s position in the healthcare technology sector and support Very Special Kids’ comprehensive care services.
Global Health Limited reported a $750K loss in income due to the end of a contract with SA Health, impacting its cash flow for the March 2025 quarter. However, the company anticipates that new sales will compensate for this loss over the next year. The company is transitioning to a SaaS business model, which is expected to reduce costs and increase margins. Investments in research and development have decreased, aligning with industry standards as products reach market readiness. Global Health is also expanding its MasterCare Plus platform and other digital solutions to new market segments, despite challenges in the Australian public healthcare sector due to funding constraints and increased demand.
Global Health Limited has secured a $1 million contract with Youturn, a community organization focused on child safety, homelessness, mental health, and suicide prevention. This three-year agreement, with potential extensions, involves deploying Global Health’s digital health SaaS solutions, including MasterCare+ and ReferralNet, to enhance Youturn’s service delivery across 12 healthcare organizations. The implementation aims to optimize operations, improve workflow standardization, and enhance accessibility, particularly benefiting regional areas. This partnership underscores Global Health’s commitment to improving productivity in health services, allowing clinicians to focus more on vulnerable mental health patients.
Global Health Limited announced the quotation of 525,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code GLH. This issuance, part of an employee incentive scheme, is expected to enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.
Global Health Limited has announced the appointment of Ms. Eryl Baron as the new Company Secretary, effective from 28 February 2025, following the resignation of Mr. James Barrie. Ms. Baron, who has been with Boardroom Pty Limited since 2020 and has experience with several ASX-listed and private companies, will work alongside Ms. Anara Malabekova, the current Joint Company Secretary, to ensure a smooth transition. This appointment signifies a strategic move for Global Health Limited as Ms. Baron will also be responsible for communication with the ASX, potentially impacting the company’s regulatory interactions and stakeholder communications.
Global Health Limited reported an 8% increase in revenue to $4.353 million for the six months ending December 2024, despite challenging conditions, with significant contributions from new and existing customers. The company reduced expenses by 3%, improved EBITDA by 55%, and achieved a 70% improvement in cash flow, indicating a positive trend towards financial stability. The company continues to focus on business development and R&D to support new market segments and enhance value-added features, while navigating difficult economic conditions in private hospitals.
Global Health Limited reported a 3.80% increase in revenue to $3,636,892 for the half-year ending December 31, 2024, but experienced a significant reduction in loss compared to the previous year. Despite this revenue growth, the company did not declare any dividends, and its net tangible assets per security decreased from the previous period. The financial outcome suggests a challenging period for Global Health Limited, with implications for stakeholders concerning the company’s financial health and future profitability.